Revlimid Trial in Multiple Myeloma Ends Enrollment Early
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive results in trial of newly diagnosed patients could further support first-line indication.
You may also be interested in...
sNDA Puts Velcade Ahead of Revlimid in Race To First-Line Multiple Myeloma Market
If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.
sNDA Puts Velcade Ahead of Revlimid in Race To First-Line Multiple Myeloma Market
If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.
Millennium Will Submit Velcade sNDA For First-Line Use In Multiple Myeloma By Year End
Strong Phase III data presented at American Society of Hematology meeting could put Velcade ahead of Celgene’s Revlimid in the front-line race.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: